Skip to main content
RHYTHM BIOSCIENCES LIMITED logo

RHYTHM BIOSCIENCES LIMITED — Investor Relations & Filings

Ticker · RHY ISIN · AU000000RHY2 LEI · 549300QOAISQ3ESJLP59 ASX Professional, scientific and technical activities
Open in API
Filings indexed 629 across all filing types
Latest filing 2026-01-28 Capital/Financing Update
Country AU Australia
Listing ASX RHY

About RHYTHM BIOSCIENCES LIMITED

https://rhythmbio.com/

Rhythm Biosciences Limited specializes in the development and commercialization of blood-based diagnostic technology for early cancer detection. The company’s primary product, ColoSTAT®, is a minimally invasive blood test designed to identify colorectal cancer by measuring specific protein biomarkers associated with the disease. ColoSTAT® is engineered to provide a reliable, cost-effective, and patient-friendly alternative to traditional screening methods, such as fecal immunochemical tests (FIT). The technology targets the global mass screening market, specifically addressing the needs of individuals who are non-compliant with current stool-based testing protocols. By facilitating higher screening participation rates, the company focuses on the early identification of colorectal cancer to improve clinical outcomes and survival rates through timely medical intervention.

Recent filings

Filing Released Lang Actions
Rhythm Biosciences secures strategic alliance with AGRF 4 pages 477.6KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 29th January 2026 from Rhythm Biosciences Ltd. It details a new strategic partnership with the Australian Genome Research Facility (AGRF) to establish commercial-scale processing capability for their geneType clinical services. The content focuses on the business development, operational benefits, and strategic implications of this partnership, including expansion plans and operational capacity. There are no financial statements, earnings data, regulatory certifications, or voting results presented. The document is a corporate announcement about a strategic partnership and operational update rather than a financial report, regulatory filing, or management report. Therefore, the most appropriate classification is a Capital/Financing Update (CAP), as it relates to business growth and operational scaling through partnership, which impacts the company's capital and commercial strategy.
2026-01-28 English
Rhythm Biosciences secures commercial alliance with CancerIQ 4 pages 642.1KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 28th January 2026 from Rhythm Biosciences Ltd. It details a strategic partnership with CancerIQ to accelerate commercial adoption of their geneType(TM) cancer risk assessment platform in the US market. The content focuses on business development, commercial strategy, and partnership details rather than financial results, regulatory filings, or management changes. There are no financial statements, earnings data, or regulatory compliance information. The document is a corporate announcement about a strategic partnership and market expansion, which fits best under Capital/Financing Update (CAP) as it relates to commercial strategy and market access expansion, which is a form of capitalizing on business growth opportunities. It is not an earnings release, annual report, or management change announcement. Therefore, the most appropriate classification is CAP with high confidence.
2026-01-27 English
Quarterly Activities Report and Appendix 4C 12 pages 921.1KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 23 January 2026, providing a detailed business update and Appendix 4C for the quarter ended 31 December 2025 (Q2 FY26). It includes comprehensive operational and commercial progress information, financial highlights such as R&D tax incentive received and loan repayment, and strategic updates including leadership changes and partnerships. The document contains substantive financial and business data for a quarterly period, not just a brief earnings highlight or a simple announcement. It is not a full annual report, audit report, or earnings release but a detailed quarterly business update with financial and operational data. This fits the definition of an Interim / Quarterly Report (IR), which must contain actual financial statements or substantive financial data and analysis for a period shorter than a full fiscal year. The document is about 15,000 characters, indicating it is a full report rather than a short announcement or certification. Therefore, the appropriate classification is IR (Interim / Quarterly Report). Q2 2026
2026-01-22 English
Landmark Publication Validates ColoSTAT Clinical Performance 6 pages 528.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 21st January 2026 from Rhythm Biosciences Ltd. It discusses the publication of clinical validation data for the ColoSTAT® blood test in a peer-reviewed journal. The announcement highlights the clinical performance, commercial opportunity, competitive advantages, and future commercialization plans of the test. It does not contain detailed financial statements, management discussion of financial results, nor is it a transcript of a call or a regulatory filing. It is a corporate announcement focused on clinical validation and commercial strategy rather than a formal financial or regulatory report. The document is lengthy (over 12,000 characters) and provides substantive information about the company's product and market positioning, but it is not an annual or interim report, audit report, or earnings release. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit into other specific categories such as earnings release, annual report, or management report.
2026-01-20 English
Application for quotation of securities - RHY 6 pages 18.4KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It details the number and type of securities to be quoted, the issue date, and related information about the securities issued as part of a previously announced transaction (Appendix 3B). This is a regulatory announcement related to capital markets activity, specifically the quotation of new securities. It is not a financial report, earnings release, or management discussion. It is also not a report publication announcement or certification. The document fits the category of Share Issue/Capital Change (SHA) because it announces the quotation of newly issued shares and related capital changes.
2026-01-15 English
Cleansing Notice 2 pages 451.7KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 16 January 2026 by Rhythm Biosciences Limited. It is a cleansing notice under Section 708A(5)(e) of the Corporations Act 2001, which relates to the issuance of shares without disclosure under Part 6D.2 of the Corporations Act. The notice confirms compliance with relevant provisions and states there is no excluded information to disclose. The document is short (4523 characters) and is a formal regulatory announcement about a share issuance event, not a financial report or detailed filing. It does not contain financial statements or detailed analysis but is a compliance notice related to capital raising. This fits the category of Capital/Financing Update (CAP) as it updates on company fundraising and capital structure changes.
2026-01-15 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.